vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

Ongoing
2
610
Europe
MK-7684A, Lenvatinib, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Advanced solid tumors, Cancer of the cervix, Uterine (endometrial), Head and Neck, Bile duct, Esophagus, Breast, Liver, Bladder, Ovarian and Gastric cancer., Diseases [C] - Cancer [C04]
 
 
KEYVIBE-002, NCT04725188 / 2020-004034-38: Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, )

Active, not recruiting
2
255
Europe, US, RoW
Pembrolizumab/Vibostolimab coformuation, MK-7684A, Docetaxel, Taxotere, Placebo
Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
01/23
08/27
KEYVIBE-004, NCT05005442 / 2021-001700-15: A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, )

Active, not recruiting
2
180
Europe, Canada, US, RoW
Pembrolizumab/vibostolimab coformuation, MK7684A
Merck Sharp & Dohme LLC
Hematological Malignancies
08/24
08/24
KEYSTEP-008, NCT04895722 / 2020-005114-18: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/)

Active, not recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A, Pembrolizumab/Favezelimab, MK-4280A, Pembrolizumab/Vibostolimab, MK-7684A, MK-4830
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Colorectal Cancer
10/25
11/25
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
2022-001371-14: A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

Ongoing
1/2
390
Europe
MK-7684A, MK-4280A, MK-7684A, MK-4280A, Powder for concentrate for solution for infusion, Solution for infusion, Solution for solution for infusion, Padcev, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Locally advanced/unresectable or metastatic urothelial carcinoma previously untreated for their advanced disease, Locally advanced or metastatic bladder cancer, Diseases [C] - Cancer [C04]
 
 
LIGHTBEAM-U01, NCT06395090: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/)

Not yet recruiting
1/2
80
NA
Pembrolizumab, MK-3475, Favezelimab, Favezelimab/Pembrolizumab, MK-4280A, Vibostolimab, Pembrolizumab/Vibostolimab, MK-7684A
Merck Sharp & Dohme LLC
Neoplasm Metastasis
06/29
06/29
MK-3475-03A, NCT04626479: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma

Active, not recruiting
1/2
400
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Favezelimab/Pembrolizumab, MK-4280A, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Vibostolimab/Pembrolizumab, MK-7684A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
05/26
05/26
KEYMAKER-U04 Substudy, NCT05845814 / 2022-001371-14: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Active, not recruiting
1/2
390
Europe, Canada, US, RoW
Coformulated favezelimab/pembrolizumab, MK-4280A, Coformulated vibostolimab/pembrolizumab, MK-7684A, EV, Padcev, ASG-22CE, ASG-22ME, Pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma, Urothelial Neoplasms
05/27
05/27
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27

Download Options